NGeneBio Co

NGeneBio Co Days Payable Outstanding

The Days Payable Outstanding (DPO) of NGeneBio Co (354200.KQ) as of Nov 17, 2026 is 107.55. In the previous year, Days Payable Outstanding (DPO) was 225.71 — a change of -52.35% (lower).

Days Payable Outstanding

107.55

YoY

-52.35%

Last updated:

Days Payable Outstanding (DPO) of NGeneBio Co is 2025 107.55 . Days Payable Outstanding (DPO) of NGeneBio Co was 2024 225.71 . It decreases by -52.35% lower compared to the previous year.

The NGeneBio Co Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2020
157.47 KRW
Jan 1, 2021
16.91 KRW
Jan 1, 2022
4.51 KRW
Jan 1, 2023
18.88 KRW
Jan 1, 2024
225.71 KRW
Jan 1, 2025
107.55 KRW
The NGeneBio Co Days Payable Outstanding history
YEARDays Payable OutstandingYoY
107.55-52.35%
225.71+1,095.25%
18.88+318.95%
4.51-73.35%
16.91-89.26%
157.47—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NGeneBio Co Stock analysis

What does NGeneBio Co do? NGeneBio Co., Ltd. generates revenue through the development and sale of diagnostic products for cancer-related genetic testing. The company offers BRCAaccuTest for hereditary breast and ovarian cancer, HEMEaccuTest for blood cancer gene testing including leukemia and lymphoma, and SOLIDaccuTest for solid cancer tissues like lung and colon cancer. Additional products include HLAaccuTest for bone marrow transplantation antigen testing, ONCOaccuPanel for large-capacity solid cancer diagnosis, and HEREDaccuTest for rare disease diagnosis. The firm also provides direct-to-consumer genetic testing and personalized healthcare services, targeting healthcare providers, hospitals, and individual consumers seeking genetic insights. The company's product portfolio serves medical institutions and patients requiring precise genetic diagnostics. HEMEaccuTest specifically addresses blood cancer types such as leukemia and lymphoma, while SOLIDaccuTest covers common solid cancers including lung and stomach cancer. ONCOaccuPanel supports comprehensive solid cancer diagnosis, and HEREDaccuTest caters to rare disease diagnostics. These products are sold to healthcare facilities and offered directly to consumers through DTC services. NGeneBio's revenue streams include sales of diagnostic kits and services, with a focus on cancer-related genetic testing. The BRCAaccuTest, HEMEaccuTest, and SOLIDaccuTest products are central to its business, targeting both clinical and direct consumer markets. Personalized healthcare services complement the product offerings, enhancing customer engagement and recurring revenue opportunities. NGeneBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NGeneBio Co stock

Days Payable Outstanding (DPO) of NGeneBio Co is 107.55 in 2025.

Days Payable Outstanding (DPO) of NGeneBio Co changed from 225.71 to 107.55, representing a -52.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) NGeneBio Co since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s NGeneBio Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — NGeneBio Co

All Key Metrics — NGeneBio Co